


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the December 2013 NCCN Trends™ Survey, which focused on Metastatic Melanoma. This survey was sent to U.S. and International users of NCCN.org.


## DEMOGRAPHICS

**Distribution of Respondent Types (n = 780)**




Note: Percentages may not total 100 because of rounding.

**Q1. Do you treat patients with metastatic melanoma? (n = 774)**




**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**



**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**

**By Geography**




Continued on Page 14

**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**

**By Geography**


- dabrafenib
- ipilimumab
- vemurafenib
- other

Continued from Page 13




**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**

**By Practice Size**




**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**

**By Practice Setting**



**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**

**By Specialty**




Continued on Page 17

**Q2. Based on the following patient characteristics, what is your preferred first-line treatment for patients with metastatic melanoma? (select one per row)**

**By Specialty**




Continued from Page 16






**Q5. When do you first test for BRAF mutation in patients with melanoma? (n = 328)**



**Q5. When do you first test for BRAF mutation in patients with melanoma?**


**By Geography**

- At initial diagnosis
- Prior to initiation of treatment in adjuvant setting
- Prior to treatment initiation in metastatic disease



**Q5. When do you first test for BRAF mutation in patients with melanoma?**


**By Practice Size**



**Q5. When do you first test for BRAF mutation in patients with melanoma?**

**By Practice Setting**


- At initial diagnosis
- Prior to initiation of treatment in adjuvant setting
- Prior to treatment initiation in metastatic disease



**Q5. When do you first test for BRAF mutation in patients with melanoma?**

**By Specialty**

- At initial diagnosis
- Prior to initiation of treatment in adjuvant setting
- Prior to treatment initiation in metastatic disease



**NCCN Trends™** is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

**Christine MacCracken, MSHEd, BSN**  
**Senior Director, Business Insights**  
**215.690.0557**  
[maccracken@nccn.org](mailto:maccracken@nccn.org)

## **National Comprehensive Cancer Network® (NCCN®)**

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.



National  
Comprehensive  
Cancer  
Network®

275 Commerce Drive • Suite 300  
Fort Washington, PA, 19034  
Telephone: 215.690.0300  
Fax: 215.690.0280

[NCCN.org](http://NCCN.org) - For Clinicians • [NCCN.org/patients](http://NCCN.org/patients) - For Patients

\*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.